U.S. District Judge Ed Kinkeade—the judge overseeing the multi-district litigation regarding DePuy Pinnacle hip implants—held a meeting on April 25, 2012 in which he discussed with both side’s attorneys the quickest way to manage the over 1,000 lawsuits contained in the MDL. A multi-district litigation is frequently used for pre-trial purposes with a goal of expediting and coordinating the consolidated pre-trial proceedings

This article will continue the discussion held by a group of attorneys during a recent Pradaxa litigation seminar. The discussion centered primarily around venue although cause of action and filing were also discussed. Boehringer’s primary American base is in Connecticut which is also the home of large numbers of insurance companies. This can lead to extremely tough jury pools and is something to consider when discussing alternative venues.

Continuing from Part One of the Pradaxa Lawsuit articles, we continue with the discussion held by attorneys who are interested in Pradaxa litigation and the issues they found to be of primary importance. Discussed at length was the RE-LY study Boehringer Ingelheim used in order to receive FDA approval

A group of attorneys interested in the Pradaxa litigation assembled to discuss the issue in a recent seminar. Pradaxa is a drug prescribed primarily for atrial fibrillation, which is essentially an irregular heartbeat.

As a continuing discussion of the science behind the medication Pradaxa, used in the treatment of atrial fibrillation, it is believed that the high incidence GI issues experienced in Pradaxa users relates directly to its unique delivery system. Pradaxa is absorbed most readily when low pH levels are present.